HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

ECOR

electroCore, Inc.

Healthcare — Medical Devices

electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an app-enabled general wellness product. It also offers non-invasive bioelectronic therapies for the treatment of chronic pain and wellness conditions. In addition, the company offers TAC-STIM for human performance and gammaCore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

None 5 analysts
$10.32
$-0.51 (-4.67%)
Target: $19.57 (89.7%)

Price History

52-Week Range
Sign in to add ECOR to a watchlist or set price alerts.

Fundamentals

Market Cap$54.86M
P/E Ratio (TTM)-
Forward P/E-11.06
EPS (TTM)$-1.77
Dividend Yield-
Profit Margin-44.08%
Revenue Growth42.60%
ROE-
Debt/Equity-
Recommendation None
Analyst Target$19.57
Analysts5
Next Earnings Aug 6, 2026 AMC
Indexes -

Technical Indicators

RSI (14)40.4
Beta0.89
SMA 20$6.41
SMA 40$7.61
52-Week High$10.50
52-Week Low$4.16
50-Day Avg$7.80
200-Day Avg$6.37
Avg Volume109.8K
Volume37.1K

Performance Analysis

NEUTRAL

ECOR presents a mixed picture with both positive and negative indicators.

- Trading near its 52-week high ($10.49), which may indicate limited upside.
~ RSI at 40.4 is in neutral territory.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
+ Strong revenue growth of 42.6% year-over-year.
- Operating at a loss with -44.1% margin.
~ Wall Street consensus is "none" from 5 analysts.
+ Average analyst target of $19.57 implies 89.7% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Aug 01, 2026 04:12 UTC

Back to Screener Export Report